Compare · BNTX vs IMVT
BNTX vs IMVT
Side-by-side comparison of BioNTech SE (BNTX) and Immunovant Inc. (IMVT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and IMVT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $22.99B, about 2.8x IMVT ($8.27B).
- Over the past year, BNTX is down 16.8% and IMVT is up 124.8% - IMVT leads by 141.5 points.
- IMVT has been more active in the news (12 items in the past 4 weeks vs 3 for BNTX).
- Both have 25 recent analyst ratings on file.
- Company
- BioNTech SE
- Immunovant Inc.
- Price
- $91.56-0.03%
- $40.26+3.32%
- Market cap
- $22.99B
- $8.27B
- 1M return
- +2.30%
- +19.70%
- 1Y return
- -16.75%
- +124.76%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2019
- News (4w)
- 3
- 12
- Recent ratings
- 25
- 25
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Immunovant Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Latest BNTX
- SEC Form 3 filed by new insider Low-Friedrich Iris Katharina
- SEC Form 3 filed by new insider Schaffert Susanne
- The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution
- SEC Form 6-K filed by BioNTech SE
- The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
- SEC Form 6-K filed by BioNTech SE
- Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
- BioNTech upgraded by UBS with a new price target
- Bernstein initiated coverage on BioNTech with a new price target
- SEC Form 6-K filed by BioNTech SE
Latest IMVT
- Chief Operating Officer Gloria Melanie sold $80,532 worth of shares (2,036 units at $39.55), decreasing direct ownership by 0.91% to 222,357 units (SEC Form 4) to satisfy withholding tax
- Chief Legal Officer Van Tuyl Christopher sold $47,702 worth of shares (1,206 units at $39.55), decreasing direct ownership by 0.67% to 179,391 units (SEC Form 4) to satisfy withholding tax
- Chief Technology Officer Stout Jay S sold $137,925 worth of shares (3,487 units at $39.55), decreasing direct ownership by 2% to 208,198 units (SEC Form 4) (tax withholding)
- Chief Executive Officer Venker Eric sold $118,980 worth of shares (3,092 units at $38.48), exercised 92,188 shares at a strike of $14.46 and returned $3,304,030 worth of shares to the company (86,629 units at $38.14), increasing direct ownership by 0.98% to 254,280 units (SEC Form 4) (withholding obligation)
- Chief Operating Officer Gloria Melanie sold $678,604 worth of shares (17,714 units at $38.31), decreasing direct ownership by 7% to 224,393 units (SEC Form 4)
- Chief Technology Officer Stout Jay S sold $1,532,309 worth of shares (40,000 units at $38.31), decreasing direct ownership by 16% to 211,685 units (SEC Form 4)
- Chief Legal Officer Van Tuyl Christopher exercised 17,824 shares at a strike of $15.20 and sold $682,887 worth of shares (17,824 units at $38.31) (SEC Form 4)
- Chief Financial Officer Girao Tiago exercised 10,000 shares at a strike of $15.90 and sold $384,600 worth of shares (10,000 units at $38.46) (SEC Form 4)
- Director Pande Atul exercised 1,500 shares at a strike of $8.43 and sold $57,015 worth of shares (1,500 units at $38.01) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Immunovant Inc.